GenSight's Lumevoq granted PIM designation by MHRA

Lumevoq (lenadogene nolparvovec) has been granted Promising Innovative Medicine (PIM) designation by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA).

GenSight Biologics (Euronext: SIGHT) is developing the gene therapy for the treatment of vision loss due to Leber hereditary optic neuropathy (LHON) caused by a confirmed G11778A mutation in the ND4 mitochondrial gene.

LHON is a rare genetic disease that results in severe and irreversible vision loss that mainly affects adolescents and young adults. The ND4 mutation is the most common and results in the worst visual outcomes, with most patients becoming legally blind. Treatment options are limited.